Goldman Sachs’s Acceleron Pharma XLRN Stock Holding History

Goldman Sachs’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-30,000	Closed	-$4.07M	–	6749
2021 Q1	$4.07M	Buy	+30,000	New	+$3.88M	﹤0.01%	3325
2020 Q2	–	Sell	-114,400	Closed	-$10.3M	–	5596
2020 Q1	$10.3M	Buy	114,400 +81,100	+244%	+$6.3M	﹤0.01%	2064
2019 Q4	$1.77M	Buy	+33,300	New	+$1.52M	﹤0.01%	3733
2016 Q2	–	Sell	-45,000	Closed	-$1.19M	–	7345
2016 Q1	$1.19M	Sell	45,000 -105,000	-70%	-$3.05M	﹤0.01%	3948
2015 Q4	$7.31M	Buy	+150,000	New	+$5.4M	﹤0.01%	2508
2015 Q3	–	Sell	-50,000	Closed	-$1.58M	–	7566
2015 Q2	$1.58M	Buy	+50,000	New	+$1.61M	﹤0.01%	4083

Goldman Sachs's XLRN Position: Q4 2021 in Review

Goldman Sachs sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 418,302 shares — an estimated $72M sold.

Goldman Sachs first reported a position in XLRN in Q4 2014 and held it in 28 quarters. The position peaked at $72M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Goldman Sachs reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 418,302 Acceleron Pharma shares in Q4 2021, an estimated $72M.
Goldman Sachs first reported a position in Acceleron Pharma in Q4 2014 and held it in 28 quarters.
Goldman Sachs's Acceleron Pharma position peaked at $72M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.